Stay updated on Pembrolizumab in ER+/HER2- Breast Cancer Clinical Trial.
Sign up to get notified when there's something new on the Pembrolizumab in ER+/HER2- Breast Cancer Clinical Trial. page.

Latest updates to the Pembrolizumab in ER+/HER2- Breast Cancer Clinical Trial. page
- Check3 days agoChange DetectedTwo NIH grant/contract entries for 2017 and 2023 were added to the study record, expanding the funding metadata. The page revision tag was updated from v3.6.5 to v3.6.6 to reflect a newer version.SummaryDifference0.0%

- Check10 days agoNo Change Detected
- Check17 days agoNo Change Detected
- Check24 days agoChange DetectedThe page now shows Revision: v3.6.5, and the Plain Language Summary section and the older Revision: v3.6.4 have been removed. This reflects an updated version tag and a change in which content is displayed to users.SummaryDifference0.0%

- Check31 days agoChange DetectedThe Ukraine location entry in the Locations list was updated to use a different transliteration (Zaporizhzhya) from Zaporizhzhia. The old entry was removed and a new one added.SummaryDifference0.0%

- Check39 days agoChange DetectedPage revision updated from v3.6.3 to v3.6.4, signaling a newer version of the study detail page. This is a metadata change rather than a substantive update to the study content.SummaryDifference0.0%

- Check60 days agoChange DetectedThe page's revision label was updated from v3.6.2 to v3.6.3, signaling a minor update to the content or metadata on the study details page.SummaryDifference0.0%

- Check67 days agoChange Detected- Revision updated from v3.6.0 to v3.6.2 on the page, signaling a new release/version behind the scenes. This does not appear to change the visible study details or user-facing content.SummaryDifference0.0%

Stay in the know with updates to Pembrolizumab in ER+/HER2- Breast Cancer Clinical Trial.
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in ER+/HER2- Breast Cancer Clinical Trial. page.